Afghanistan
Tuberculosis profile
| High TB burden |
Population  2012 30 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 11 (4.6–20) 37 (15–68)
Mortality (HIV+TB only) 0.087 (<0.01–0.33) 0.29 (0.01–1.1)
Prevalence  (includes HIV+TB) 110 (54–180) 358 (181–595)
Incidence  (includes HIV+TB) 56 (47–67) 189 (156–226)
Incidence (HIV+TB only) 0.31 (0.19–0.46) 1 (0.63–1.5)
Case detection, all forms (%) 51 (43–62)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 13 319 (48) Relapse 1 049 (54)
Smear-negative 4 740 (17) Treatment after failure 160 (8)
Smear-unknown / not done 2 665 (10) Treatment after default 37 (2)
Extrapulmonary 6 906 (25) Other 702 (36)
Other          
Total new 27 630   Total retreatment 1 948  
           
Other (history unknown)          
Total new and relapse 28 679   Total cases notified 29 578  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 0.5 0.7  
Age < 15 588 2 455  
Laboratories 2012
Smear (per 100 000 population) 2.0
Culture (per 5 million population) 0.3
Drug susceptibility testing (per 5 million population) 0
Is second-line drug susceptibility testing available? Yes, outside
country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 91   Is rifampicin used
throughout treatment for
new patients?
No
New smear-negative/extrapulmonary 84  
Retreatment 77  
TB/HIV 2012 Number (%)
TB patients with known HIV status 7 275 (25)
HIV-positive TB patients 5 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 5 (100)
HIV-positive TB patients on antiretroviral therapy (ART) 5 (100)
HIV-positive people screened for TB 80  
HIV-positive people provided with IPT 25  
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 3.5 (0.1–12) 32 (7.5–56)
MDR-TB cases among notified pulmonary
TB cases
730 (21–2 500) 620 (150–1 100)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB   38 (2%) 38
Laboratory-confirmed MDR-TB cases   31 31
Patients started on MDR-TB treatment     38
Financing TB control 2013
National TB programme budget (US$ millions) 13
% Funded domestically 3%
% Funded internationally 65%
% Unfunded 32%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-23 Data: www.who.int/tb/data